Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without ASO3 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial

• Published in: JAMA : the journal of the American Medical Association Vol. 314; no. 3; p. 237
• Main Authors: Jackson, Lisa A, Campbell, James D, Frey, Sharon E, Edwards, Kathryn M, Keitel, Wendy A, Kotloff, Karen L, Berry, Andrea A, Graham, Irene, Atmar, Robert L, Creech, C Buddy, Thomsen, Isaac P, Patel, Shital M, Gutierrez, Andres F, Anderson, Edwin L, El Sahly, Hana M, Hill, Heather, Noah, Diana L, Bellamy, Abbie R
• Format: Journal Article
• Language: English
• Published: Chicago American Medical Association 21.07.2015
• Subjects: Clinical outcomes; Drug dosages; Influenza; Public health; Vaccines; Virology; China
• ISSN: 0098-7484; 1538-3598

Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continue to occur. Hemagglutinin H7 administered alone is a poor immunogen necessitating evaluation of adjuvanted H7N9 vaccines. Here, Jackson et al evaluate the immunogenicity and safety of an inactivated H7N9 vaccine with and without AS03 adjuvant, as well as mixed vaccine schedules that included sequential administration of AS03- and MF59-containing formulations and of adjuvanted and unadjuvanted formulations. The AS03 and MF59 adjuvants augmented the immune responses to 2 doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest titers. This study of 2 adjuvants used in influenza vaccine formulations with adjuvant mixed on site provides immunogenicity information that may be informative to influenza pandemic preparedness programs.